Suppression of Ketogenesis in Type 1 Diabetes Is Not Delayed by SGLT2 Inhibitor Therapy
SIEBEL S, PATEL N, GALDERISI A, CARRIA L, TAMBORLANE W, SHERR J. Suppression of Ketogenesis in Type 1 Diabetes Is Not Delayed by SGLT2 Inhibitor Therapy. Diabetes 2018, 67 DOI: 10.2337/db18-117-lb.Peer-Reviewed Original ResearchPlasma glucoseSGLT2i useBHB levelsMedtronic MiniMedBoehringer Ingelheim GmbHSGLT2 inhibitor therapyInterruption studiesRapid-acting insulinType 1 diabetesRisk of DKABasal insulin infusionEli LillySuppression of ketogenesisCanagliflozin therapyRescue doseSGLT2i therapySGLT2i treatmentBasal insulinInhibitor therapySGLT2 inhibitorsT1D patientsAdjunctive agentsMetabolic decompensationInsulin infusionJanssen Pharmaceuticals